Last reviewed · How we verify
1-MNA
At a glance
| Generic name | 1-MNA |
|---|---|
| Sponsor | Pharmena North America |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Implementation of a Personalised Health Plan (PHP) on Patient Quality of Life Score at 2-year Follow-up (NA)
- Dysphagia Management for Caregivers of Stroke Patients (NA)
- Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life (NA)
- Frailty and Health-related Quality of Life in Older Women With Breast Carcinoma
- G8, CARG, Frailty, and Nutritional Markers in Predicting Chemotoxicity
- Sarcopenia and Related Factors in Patients With Multiple Sclerosis
- Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty (NA)
- Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to Intensive Care for Sepsis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1-MNA CI brief — competitive landscape report
- 1-MNA updates RSS · CI watch RSS
- Pharmena North America portfolio CI